EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

Lama Abujamous, Abderrezzaq Soltani, Hamda Al-Thawadi, Abdelali Agouni

Biomolecules and Biomedicine · 2024

DOI: 10.17305/bb.2023.9757 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Lama Abujamous und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar; Office of Vice President for Research and Gradua…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Genital Neoplasms, Male. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced ovarian cancer is a malignancy that spreads beyond the ovaries to the pelvis, abdomen, lungs, or lymph nodes. Effective treatment options are available to improve survival rates in patients with advanced ovarian cancer. These include radiation, surgery, chemotherapy, immunotherapy, and targeted therapy. Drug resistance, however, remains a significant challenge in pharmacotherapeutic interventions, leading to reduced efficacy and unfavorable patient outcomes. Combination therapy, which involves using multiple drugs with different mechanisms of action at their optimal dose, is a promising approach to circumvent this challenge and it involves using multiple drugs with different mechanisms of action at their optimal dose. In recent years, nanotechnology has emerged as a valuable alternative for enhancing drug delivery precision and minimize toxicity. Nanoparticles can deliver drugs to specific cancer cells, resulting in higher drug concentrations at the tumor site, and reducing overall drug toxicity. Nanotechnology-based drug delivery systems have the potential to improve the therapeutic effects of anti-cancer drugs, reduce drug resistance, and improve outcomes for patients with advanced ovarian cancer. This literature review aims to examine the current understanding of combining poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy in treating advanced ovarian cancer and the potential impact of nanotechnology on drug delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsGenital Neoplasms, MaleHumansFemalePoly(ADP-ribose) Polymerase InhibitorsCarcinoma, Ovarian EpithelialDrug Delivery SystemsImmunotherapy

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar; Office of Vice President for Research and Graduate Studies, Qatar University, Doha, Qatar.
  • Office of Vice President for Medical and Health Sciences, Qatar University, Doha, Qatar; Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
  • Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar.
  • Office of Vice President for Research and Graduate Studies, Qatar University, Doha, Qatar; Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.

Zitieren

APA

Abujamous, L., Soltani, A., Al-Thawadi, H., & Agouni, A. (2024). Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2023.9757

Vancouver

Abujamous L, Soltani A, Al-Thawadi H, Agouni A. Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2023.9757

BibTeX
@article{Abujamous2024,
  author = {Abujamous, Lama and Soltani, Abderrezzaq and Al-Thawadi, Hamda and Agouni, Abdelali},
  title = {Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer},
  journal = {Biomolecules and Biomedicine},
  year = {2024},
  doi = {10.17305/bb.2023.9757}
}
Kostenlos starten →